Incidence of adverse events associated with use of perflutren contrast agents for echocardiography.
about
Update on the safety and efficacy of commercial ultrasound contrast agents in cardiac applicationsContrast Ultrasound Imaging Does Not Affect Heat Shock Protein 70 Expression in Cholesterol-Fed Rabbit Aorta.Effect of surface architecture on in vivo ultrasound contrast persistence of targeted size-selected microbubbles.The role of poly(ethylene glycol) brush architecture in complement activation on targeted microbubble surfacesContrast Ultrasound Imaging of the Aorta Does Not Affect Progression of Atherosclerosis or Cardiovascular Biomarkers in ApoE-/- Mice.Feasibility of Retrograde Ureteral Contrast Injection to Guide Ultrasonographic Percutaneous Renal Access in the Nondilated Collecting System.Safety of Perflutren Ultrasound Contrast Agents: A Disproportionality Analysis of the US FAERS Database.The Feasibility and Clinical Utility of Microsphere Contrast-enhanced Transthoracic Echocardiography in Adult Congenital Heart Disease.New-onset seizure after perflutren microbubble injection during dobutamine stress echocardiography.Implementation of echocardiographic contrast agents into clinical practice: a United Kingdom National Health Service Survey on behalf of the British Society of Echocardiography.Contrast-enhanced ultrasound of the liver: technical and lexicon recommendations from the ACR CEUS LI-RADS working group.Analysis of the quantitative improvements in resting echocardiographic image sharpness through the use of contrast enhanced echocardiography.Contrast enhanced ultrasound guided biopsies of liver lesions not visualized on standard B-mode ultrasound-preliminary experience.
P2860
Q28085632-ED86E184-459D-4650-B2A6-543B7F5D55DBQ30394923-AFCED25F-5A30-4FC8-A1E8-2B2862A163CEQ30457849-CD1A02AD-7E36-45C9-A910-6477D1DE6DBDQ30464013-00E8689F-A751-49A5-AA6E-F73E2BD8DB2EQ35754675-840987DF-670F-4D41-B524-757A3355BA6DQ38799147-A2D2C208-BB09-4010-BD63-D4827848911EQ39133567-DFF00713-C16D-4616-9AD5-8FCD8C761B58Q41411415-2B30A95F-5337-4177-AE83-75DBB0EE796CQ42712804-CECE6BEF-73EC-4882-8E64-5C588F18F0D8Q44104216-B9420935-FF4C-443B-806B-008DE4C9F133Q46088451-43933150-F844-4851-8C78-9A3B1520F59AQ46600418-0D14F11D-987C-484C-96F7-0E0AD954D2C8Q47098835-827F0AB3-8D6F-4779-83C5-6F723AA656A1
P2860
Incidence of adverse events associated with use of perflutren contrast agents for echocardiography.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Incidence of adverse events as ...... t agents for echocardiography.
@en
Incidence of adverse events as ...... t agents for echocardiography.
@nl
type
label
Incidence of adverse events as ...... t agents for echocardiography.
@en
Incidence of adverse events as ...... t agents for echocardiography.
@nl
prefLabel
Incidence of adverse events as ...... t agents for echocardiography.
@en
Incidence of adverse events as ...... t agents for echocardiography.
@nl
P356
P1476
Incidence of adverse events as ...... t agents for echocardiography.
@en
P2093
Charles A Herzog
P304
P356
10.1001/JAMA.299.17.2023
P407
P577
2008-05-01T00:00:00Z